EXELIXIS, INC. (EXEL)
Clinical trial NCT05176483 updates: 1. primary completion date: 2030-06-28 → 2027-01-31 2. enrollment: 1314 → 1394 participants 3. allocation: NON_RANDOMIZED → RANDOMIZED
Clinical trial NCT05176483 updates: 1. primary completion date: 2030-06-28 → 2027-01-31 2. enrollment: 1314 → 1394 participants 3. allocation: NON_RANDOMIZED → RANDOMIZED
📉 **NEGATIVE** • Medium confidence analysis (62%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (24%) **Content type:** Clinical